VBIO

VBIO (which files as Tivic Health Systems) is a $1.44M-market-cap clinical-stage biopharma mid-pivot, and the numbers describe a company being rebuilt from scratch, not a going business. Management explicitly flags 'our ability to continue as a going concern' and 'our ability to secure additional financing on favorable terms, if at all' in its forward-looking statements — the polite language of a company that must raise capital to survive. It has wound down its only commercial product (the ClearUP bioelectronic device, ~$347K in exit charges), so the trailing revenue base of $780K (FY2024, already -33.7% YoY) effectively goes away: management concedes it 'will generate minimal revenue during this transition.' What remains is an in-licensed late-stage asset, Entolimod, that has not yet reached a Biologics License Application — the stated 'immediate operational priority' is merely validating the manufacturing process needed to submit the BLA. There is no approved product and no product revenue engine.

The financials confirm the speculative profile. FY2025 net loss was -$8.88M (worse by 57%), operating income -$7.90M, and operating cash flow -$7.00M. Margins are not meaningful in any conventional sense — operating margin of -1012% and net margin of -1138% simply reflect spend against a revenue base near zero. R&D more than doubled (+138% to $3.13M) as the company funds the TLR5 pipeline, and the accumulated deficit sits at -$52.6M. The one genuine positive is liquidity: cash rose to $12.6M and current assets ($13.0M) dwarf current liabilities ($646K), giving perhaps two years of runway at the current burn. But that cash was bought with extraordinary dilution — shares outstanding jumped 364% in a year — and total assets ballooned 1026% (to $31.6M) largely on acquired/licensed intangibles from the Statera license and Scorpius/Velocity CDMO deal, while liabilities rose 2635%. This is a balance sheet assembled through financing and M&A, not earned.